NWPharmaTech’s expert team combines academic research, cutting-edge technology and clinical development to bring to market new drug formulations targeting mental health conditions.
These therapeutic interventions will support a return to homeostasis, empowering patients to lead longer and healthier lives.
Initial Target Indications – Psychiatric and Neurological Disorders
We are advancing to late-stage clinic development in two primary areas: Clinical High Risk for Psychosis & General Anxiety Disorder.
We are a driven team of specialists, committed to advancing research in Psychiatric and Neurological Disorders. Our team has experience across multiple sectors – pharmaceutical operations, research and development, intellectual property, marketing and finance – and is based in the UK, Europe and North America.